BMS Archive

Plant · Scientific monograph

Crocus sativus

Saffron / Saffron Crocus

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Cognitive Function Research, Neurological & Cognitive Research, Mood & Neuropsychiatric Research, Oxidative Stress Research

Research overview

Historical use

Saffron is the dried stigma of Crocus sativus, a cultivated Iridaceae geophyte historically used across Persian, Mediterranean, Indian, and Middle Eastern medical and culinary traditions. Traditional uses included mood, menstrual, digestive, and general tonic indications; these are historical records and do not establish clinical efficacy.

Modern research context

Saffron is one of the better-studied botanical candidates in dementia-related cognitive research. Systematic reviews and meta-analyses of randomized trials report benefits versus placebo in mild cognitive impairment or Alzheimer's disease outcomes, but also note small samples, overlapping research groups, and risk-of-bias concerns [1][2]. A 22-week randomized trial found Crocus sativus 30 mg/day comparable to donepezil 10 mg/day in mild-to-moderate Alzheimer's disease, with different adverse-event patterns [3]. A placebo-controlled 16-week trial in mild-to-moderate Alzheimer's disease and a 12-month comparator trial against memantine in moderate-to-severe Alzheimer's disease further support research interest, but confirmatory independent trials are still needed [4][5].

Adverse effects

Clinical trials in cognitive disorders generally reported similar tolerability to comparator or placebo, with no consistent serious adverse-event signal in the reviewed RCTs [1][2][5]. Reported or plausible adverse effects include nausea, appetite change, dizziness, headache, dry mouth, and allergic reactions. High-dose saffron outside trial ranges is not equivalent to the 30 mg/day extract used in most dementia trials.

Contraindications

Avoid in known allergy to saffron or Crocus species. Use caution with anticoagulant or antiplatelet medications because saffron constituents have platelet and vascular effects in preclinical literature, although cognition trials do not establish a clinically graded interaction. Use during pregnancy is not recommended at medicinal doses because traditional and pharmacological sources raise uterotonic concerns and cognition trials did not study pregnant populations.

Clinical and phytochemical data

Used part

Dried stigma; clinical trials typically used saffron extract capsules around 30 mg/day.

Primary active compounds

  • Crocin

  • Crocetin

  • Safranal

  • Picrocrocin

  • Kaempferol glycosides

  • Crocus sativus stigma carotenoids

Mechanism of action

Cognitive mechanisms under investigation include antioxidant carotenoid activity, modulation of amyloid-beta aggregation, and cholinergic effects relevant to acetylcholinesterase [1][2]. Crocin and crocetin are studied for reduction of oxidative stress and inflammatory signaling through pathways such as NF-kB and Nrf2, primarily in preclinical models [1][2]. Comparator trials in Alzheimer's disease provide clinical outcome signals but do not prove disease modification [3][5].

Pharmacokinetics

Absorption

Human pharmacokinetic data for saffron extract as a whole are limited. Crocin is poorly absorbed intact and is hydrolyzed in the intestine to crocetin, which is more readily absorbed; cognition trials generally do not provide detailed plasma concentration data [1][2].

Distribution

Human tissue-distribution data are insufficient. Crocetin is more lipophilic than crocin and may distribute systemically after absorption, but direct human brain-distribution data for saffron extract are not established [1][2].

Metabolism

Crocin undergoes intestinal hydrolysis to crocetin followed by conjugation reactions. Safranal is expected to undergo hepatic metabolism; clinically relevant CYP450 interaction data for standard saffron extract doses are not established [1][2].

Excretion

Conjugated metabolites are expected to be eliminated through urinary and biliary routes. Human elimination half-life values for cognition-relevant saffron extract constituents are not established in the cited cognitive trials [1][2].

Safety and interactions

Drug interactions

No clinically graded interaction trials were identified for saffron in cognitive-disorder populations. Precautionary concerns include additive effects with anticoagulant or antiplatelet drugs, CNS-active drugs, and antihypertensives; these are based on pharmacology rather than direct interaction trials [1][2].

Toxicity

Clinical trials commonly used 30 mg/day for 16 to 52 weeks and did not report a consistent serious adverse-event excess [1][3][4][5]. Long-term high-dose use outside studied ranges is not characterized by these trials, and medicinal-dose use in pregnancy is not supported.

Special precautions

Pregnancy

Insufficient pregnancy data for medicinal-dose saffron extract. Avoid medicinal doses because pregnant participants were not studied and uterotonic concerns exist outside the cognition-trial literature.

Lactation

Insufficient data on saffron constituents in human milk. Avoid medicinal-dose preparations during lactation as a precaution.

Hepatic impairment

No formal hepatic-impairment studies. Use caution in significant liver disease because safranal and carotenoid metabolites undergo hepatic processing.

Renal impairment

No formal renal-impairment studies. No dose-adjustment guidance has been established.

Sources and references

  1. [1] - Ayati Z et al. The efficacy of Crocus sativus (saffron) versus placebo and common drugs in the treatment of cognitive disorders: a systematic review and meta-analysis. BMC Complement Med Ther, 2020. PMID: 33167948
  2. [2] - Avgerinos KI et al. Effects of saffron (Crocus sativus L.) on cognitive function: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci, 2020. PMID: 32445136
  3. [3] - Akhondzadeh S et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology (Berl), 2010. PMID: 19838862
  4. [4] - Akhondzadeh S et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther, 2010. PMID: 20831681
  5. [5] - Farokhnia M et al. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Hum Psychopharmacol, 2014. PMID: 25163440

Additional source links

Continue browsing